Biomea Fusion, Inc. (BMEA)Healthcare | Biotechnology | San Carlos, United States | NasdaqGS
2.21 USD
+0.28
(14.508%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.20 -0.01 (-0.013%) ⇩ (April 17, 2026, 7:44 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:44 p.m. EDT
Biomea Fusion is a high-risk speculative vehicle where the upcoming clinical trial readouts and equity raisings will dictate a binary move, but the current technical setup is perilous. With negative earnings, a -2% short-term forecast from the model, and massive short interest, the stock is fundamentally broken. The bullish options flow on 3-6 month horizons appears to be a 'lottery ticket' strategy by speculators betting on a trial catalyst, while intelligent capital is positioning puts to catch potential failure or liquidity dry-ups before the latest financing milestone. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.126899 |
| AutoARIMA | 0.128584 |
| AutoETS | 0.128585 |
| AutoTheta | 0.128648 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 7.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.146 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.377 |
| Market Cap | 159,781,760 |
| Forward P/E | -2.08 |
| Beta | -0.27 |
| Website | https://biomeafusion.com |
As of April 18, 2026, 10:44 p.m. EDT: Speculators are displaying a aggressive bullish bias on the long end despite recent price weakness. April expiration shows dominant Iron Condor/Unusual Put positioning at the 2.0 and 1.5 strikes (highest OI), indicating a strong defensive floor for the next week. However, July and October expirations show massive volume and Open Interest in out-of-the-money calls (strikes 2.5, 3.0, 5.0). This suggests traders are betting on a significant 'blow-off top' or gamma spike push to cover short call exposure later in the year, decoupled from near-term downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.28488374 |
| Address1 | 1,599 Industrial Road |
| All Time High | 43.69 |
| All Time Low | 0.872 |
| Ask | 2.5 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 2,327,140 |
| Average Daily Volume3 Month | 1,350,119 |
| Average Volume | 1,350,119 |
| Average Volume10Days | 2,327,140 |
| Beta | -0.265 |
| Bid | 1.58 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.409 |
| City | San Carlos |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.21 |
| Current Ratio | 5.229 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.215 |
| Day Low | 1.9501 |
| Debt To Equity | 5.377 |
| Display Name | Biomea Fusion |
| Earnings Timestamp | 1,774,382,400 |
| Earnings Timestamp End | 1,777,924,800 |
| Earnings Timestamp Start | 1,777,924,800 |
| Ebitda | -79,898,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.321 |
| Enterprise Value | 105,558,760 |
| Eps Current Year | -0.98101 |
| Eps Forward | -1.06097 |
| Eps Trailing Twelve Months | -1.18 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.4328 |
| Fifty Day Average Change | 0.7772 |
| Fifty Day Average Change Percent | 0.54243433 |
| Fifty Two Week Change Percent | 28.488373 |
| Fifty Two Week High | 3.08 |
| Fifty Two Week High Change | -0.8699999 |
| Fifty Two Week High Change Percent | -0.2824675 |
| Fifty Two Week Low | 0.872 |
| Fifty Two Week Low Change | 1.338 |
| Fifty Two Week Low Change Percent | 1.5344038 |
| Fifty Two Week Range | 0.872 - 3.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,618,579,800,000 |
| Float Shares | 67,444,533 |
| Forward Eps | -1.06097 |
| Forward P E | -2.0829997 |
| Free Cashflow | -42,026,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.072270006 |
| Held Percent Institutions | 0.37348998 |
| Implied Shares Outstanding | 72,299,440 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-04-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California. |
| Long Name | Biomea Fusion, Inc. |
| Market | us_market |
| Market Cap | 159,781,760 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_695310535 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -61,797,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 159,058,768 |
| Number Of Analyst Opinions | 6 |
| Open | 1.98 |
| Operating Cashflow | -70,371,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 980 9099 |
| Post Market Change | -0.012599945 |
| Post Market Change Percent | -0.57013327 |
| Post Market Price | 2.1974 |
| Post Market Time | 1,776,469,474 |
| Previous Close | 1.93 |
| Price Eps Current Year | -2.2527802 |
| Price Hint | 4 |
| Price To Book | 5.403423 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.028 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.57143 |
| Region | US |
| Regular Market Change | 0.28 |
| Regular Market Change Percent | 14.5078 |
| Regular Market Day High | 2.215 |
| Regular Market Day Low | 1.9501 |
| Regular Market Day Range | 1.9501 - 2.215 |
| Regular Market Open | 1.98 |
| Regular Market Previous Close | 1.93 |
| Regular Market Price | 2.21 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 3,293,390 |
| Return On Assets | -0.73376 |
| Return On Equity | -1.5235001 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 72,299,440 |
| Shares Percent Shares Out | 0.1767 |
| Shares Short | 12,774,281 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 11,326,632 |
| Short Name | Biomea Fusion, Inc. |
| Short Percent Of Float | 0.21 |
| Short Ratio | 9.57 |
| Source Interval | 15 |
| State | CA |
| Symbol | BMEA |
| Target High Price | 12.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.16667 |
| Target Median Price | 6.5 |
| Total Cash | 55,812,000 |
| Total Cash Per Share | 0.772 |
| Total Debt | 1,589,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.53562 |
| Two Hundred Day Average Change | 0.67438006 |
| Two Hundred Day Average Change Percent | 0.43915817 |
| Type Disp | Equity |
| Volume | 3,293,390 |
| Website | https://biomeafusion.com |
| Zip | 94,070 |